D. Boral Capital Reaffirms “Buy” Rating for Hoth Therapeutics (NASDAQ:HOTH)

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating reissued by investment analysts at D. Boral Capital in a note issued to investors on Wednesday,Benzinga reports. They presently have a $5.00 price target on the stock. D. Boral Capital’s price target would indicate a potential upside of 395.05% from the stock’s previous close.

A number of other equities research analysts have also recently issued reports on the stock. Wall Street Zen cut shares of Hoth Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Hoth Therapeutics in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $5.00.

Hoth Therapeutics Price Performance

NASDAQ:HOTH opened at $1.01 on Wednesday. The company has a market capitalization of $15.67 million, a price-to-earnings ratio of -0.95 and a beta of 0.50. The business has a 50 day moving average of $1.00 and a 200 day moving average of $1.24. Hoth Therapeutics has a 1-year low of $0.66 and a 1-year high of $2.12.

Institutional Investors Weigh In On Hoth Therapeutics

A number of large investors have recently added to or reduced their stakes in HOTH. DRW Securities LLC bought a new position in shares of Hoth Therapeutics during the fourth quarter valued at about $257,000. Geode Capital Management LLC increased its holdings in Hoth Therapeutics by 18.0% during the 4th quarter. Geode Capital Management LLC now owns 181,112 shares of the company’s stock valued at $179,000 after purchasing an additional 27,577 shares during the period. Citadel Advisors LLC bought a new position in Hoth Therapeutics during the 3rd quarter valued at approximately $232,000. Virtu Financial LLC purchased a new stake in Hoth Therapeutics in the 3rd quarter worth approximately $184,000. Finally, Kestra Private Wealth Services LLC bought a new stake in shares of Hoth Therapeutics in the 3rd quarter worth approximately $51,000. Institutional investors own 7.08% of the company’s stock.

About Hoth Therapeutics

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.